These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 8239624)

  • 1. In vitro activities of BAY Y3118, ciprofloxacin, ofloxacin, and fleroxacin against gram-positive and gram-negative pathogens from respiratory tract and soft tissue infections.
    Bongaerts GP; Hoogkamp-Korstanje JA
    Antimicrob Agents Chemother; 1993 Sep; 37(9):2017-9. PubMed ID: 8239624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
    Hoogkamp-Korstanje JA
    J Antimicrob Chemother; 1997 Sep; 40(3):427-31. PubMed ID: 9338498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of BAY 12-8039, a new fluoroquinolone.
    Woodcock JM; Andrews JM; Boswell FJ; Brenwald NP; Wise R
    Antimicrob Agents Chemother; 1997 Jan; 41(1):101-6. PubMed ID: 8980763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro evaluation of BAY Y3118, a new full-spectrum fluoroquinolone.
    Bremm KD; Petersen U; Metzger KG; Endermann R
    Chemotherapy; 1992; 38(6):376-87. PubMed ID: 1288961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The comparative activity of fleroxacin, three other quinolones and eight unrelated antimicrobial agents.
    McCarter YS; Mazens-Sullivan MF; Bartlett RC
    Chemotherapy; 1992; 38(5):308-18. PubMed ID: 1337507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study.
    Hoban DJ; Bouchillon SK; Johnson JL; Zhanel GG; Butler DL; Miller LA; Poupard JA;
    Diagn Microbiol Infect Dis; 2001; 40(1-2):51-7. PubMed ID: 11448564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative antimicrobial activity of lomefloxacin, norfloxacin, ofloxacin, ciprofloxacin and enoxacin against > 500 bacterial isolates.
    Ismaeel NA; Tayeb OS
    Microbios; 1993; 74(300):147-54. PubMed ID: 8396196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial activity of DV-7751a, a new fluoroquinolone.
    Tanaka M; Hoshino K; Ishida H; Sato K; Hayakawa I; Osada Y
    Antimicrob Agents Chemother; 1993 Oct; 37(10):2112-8. PubMed ID: 8257132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-vitro activity of four new fluoroquinolones.
    García-Rodríguez JA; García Sánchez JE; García García MI; Fresnadillo MJ; Trujillano I; García Sánchez E
    J Antimicrob Chemother; 1994 Jul; 34(1):53-64. PubMed ID: 7961215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro antibacterial activities of DQ-113, a potent quinolone, against clinical isolates.
    Tanaka M; Yamazaki E; Chiba M; Yoshihara K; Akasaka T; Takemura M; Sato K
    Antimicrob Agents Chemother; 2002 Mar; 46(3):904-8. PubMed ID: 11850285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo evaluations of A-80556, a new fluoroquinolone.
    Clement JJ; Tanaka SK; Alder J; Vojtko C; Beyer J; Hensey D; Ramer N; McDaniel D; Chu DT
    Antimicrob Agents Chemother; 1994 May; 38(5):1071-8. PubMed ID: 8067740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of Bay y3118 against quinolone-susceptible and -resistant gram-negative and gram-positive bacteria.
    Piddock LJ; Marshall AJ; Jin YF
    Antimicrob Agents Chemother; 1994 Mar; 38(3):422-7. PubMed ID: 8203834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone.
    Dalhoff A; Petersen U; Endermann R
    Chemotherapy; 1996; 42(6):410-25. PubMed ID: 8957575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antibacterial activity of gatifloxacin against various fresh clinical isolates in 2002].
    Matsuzaki K; Watabe E; Yoshimori K; Shikano M; Sato Y; Hasegawa M; Kobayashi I
    Jpn J Antibiot; 2002 Dec; 55(6):800-7. PubMed ID: 12621734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of temafloxacin against gram-negative bacteria: an overview.
    Hardy DJ
    Am J Med; 1991 Dec; 91(6A):19S-23S. PubMed ID: 1662890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo activities of a new quinolone, WIN 57273, possessing potent activity against gram-positive bacteria.
    Sedlock DM; Dobson RA; Deuel DM; Lesher GY; Rake JB
    Antimicrob Agents Chemother; 1990 Apr; 34(4):568-75. PubMed ID: 2344163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro antibacterial activity of the new quinolone Bay y3118 against clinical isolates.
    Ravizzola G; Pizzi R; Pirali F; Turano A
    J Chemother; 1994 Dec; 6(6):392-8. PubMed ID: 7699426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative in vitro activity of lomefloxacin, a difluoro-quinolone.
    Robbins MJ; Baskerville AJ; Sanghrajka M; Mumtaz G; Felmingham D; Ridgway GL; Grüneberg RN
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):65S-76S. PubMed ID: 2791500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
    Malmborg AS; Ahlén S
    Chemotherapy; 1993; 39(1):32-5. PubMed ID: 8383030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative in vitro activities of five quinolone antibiotics, including gemifloxacin, against clinical isolates.
    Gönüllü N; Aktaş Z; Salcioglu M; Bal C; Ang O
    Clin Microbiol Infect; 2001 Sep; 7(9):499-503. PubMed ID: 11678934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.